Document is current
Any future updates will be listed below
-
Authors
Bagel, Jerry https://orcid.org/0000-0001-5241-0915
Gogineni, Ranga https://orcid.org/0009-0002-9140-9196
Shaikh, Asif
Lebwohl, Mark G. https://orcid.org/0000-0002-4705-5303
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01722331 at ClinicalTrials.govnct01729754 at ClinicalTrials.govDocuments that mention this clinical trial
SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.6730
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00743-7
AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2
https://doi.org/10.1136/annrheumdis-2021-eular.1827
Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2
https://doi.org/10.1007/s13555-026-01708-y
AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.2983
THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials
https://doi.org/10.1136/annrheumdis-2018-eular.6782
Documents that mention this clinical trial
SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.6730
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00743-7
Old and new treatment targets in axial spondyloarthritis
https://doi.org/10.1136/rmdopen-2015-000054
Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2
https://doi.org/10.1007/s13555-026-01708-y
AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
https://doi.org/10.1136/annrheumdis-2018-eular.2983
THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials
https://doi.org/10.1136/annrheumdis-2018-eular.6782
AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders
https://doi.org/10.1136/annrheumdis-2018-eular.6758
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme
Sun Pharma
- License Information
-
More Information
Article History
Received: 31 December 2025
Accepted: 23 February 2026
First Online: 16 March 2026
Declarations
:
: Dr. Jerry Bagel has received research funds for the Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Corrona LLC, Dermavant Sciences, Dermira, Glenmark Pharmaceuticals Ltd, Janssen, Kadmon Corporation, LEO Pharma, Lilly, Lycera Corp, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, Taro Pharmaceutical Industries Ltd, and UCB; is or has been a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Janssen, Lilly, Novartis, Sun Pharma, and UCB; and is or has been a speaker for AbbVie, Celgene Corporation, Eli Lilly, Janssen, and Novartis. Dr. Ranga Gogineni is an employee of Sun Pharmaceutical Industries, Inc. Dr. Asif Shaikh is an employee of Sun Pharmaceutical Industries, Inc. Dr. Mark G. Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Arcutis Biotherapeutics, Avotres Therapeutics, Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio, Apogee, Arcutis Biotherapeutics, AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica.
: The reSURFACE 1 and reSURFACE 2 study protocols were reviewed and approved by local institutional review boards or ethics panels. All participants provided written informed consent. The studies were conducted in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki.
